Wedbush downgraded Design Therapeutics to Neutral from Outperform with a $6 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DSGN:
- Multiple Downgrades Send Design Therapeutics (NASDAQ:DSGN) Down in Flames
- Design Therapeutics downgraded to Market Perform from Outperform at SVB Securities
- Design Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- Design: Variability of results limited utility of FXN protein measurement
- Design Therapeutics reports Q2 EPS (36c), consensus (40C)